Thrombolytic TherapyStreptokinaseTissue Plasminogen ActivatorFibrinolytic AgentsMyocardial InfarctionMortalityPlasminogen ActivatorsAnistreplaseStrokeUrokinase-Type Plasminogen ActivatorTreatment OutcomeTime FactorsHospital MortalityPulmonary EmbolismBrain IschemiaCerebral HemorrhageHeparinMyocardial ReperfusionAcute DiseaseEmbolectomyThrombosisProspective StudiesCoronary Care UnitsFibrinolysisRetrospective StudiesHemorrhageElectrocardiographyHeart Rupture, Post-InfarctionIntracranial ThrombosisFollow-Up StudiesIntracranial HemorrhagesInfant MortalityRecurrenceInfusions, IntravenousAngioplasty, Balloon, CoronarySurvival AnalysisFibrinolysinCarotid Artery ThrombosisCoronary AngiographyEmergency Medical ServicesCoronary ThrombosisEmergenciesTomography, X-Ray ComputedInjections, IntravenousVascular PatencyIntracranial Embolism and ThrombosisRecombinant ProteinsEmergency TreatmentInfusions, Intra-ArterialSurvival RatePrognosisAnticoagulantsIntracranial EmbolismVenous ThrombosisCause of DeathCerebral InfarctionHirudin TherapyCreatine KinasePredictive Value of TestsRisk FactorsEmergency Medical TechniciansRadionuclide VentriculographyThrombectomyRandomized Controlled Trials as TopicInjections, Intra-ArterialReperfusionRegistriesCohort StudiesFibrinopeptide ACerebral AngiographyMultivariate AnalysisFibrinogenCerebrovascular DisordersFibrinEye HemorrhageIncidenceAge FactorsNewfoundland and LabradorProportional Hazards ModelsPatient SelectionAspirinHeart RuptureAngiographyDrug Therapy, CombinationCatheterization, PeripheralRisk AssessmentStreptodornase and StreptokinaseChild MortalitySeverity of Illness IndexShock, CardiogenicArterial Occlusive DiseasesInfarction, Middle Cerebral ArteryBlood CoagulationEcchymosisCardiac CatheterizationHospitals, CommunityFibrin Fibrinogen Degradation ProductsMaternal MortalityUnited StatesLogistic Models